149 related articles for article (PubMed ID: 25076421)
1. A rapid improvement in obsessive-compulsive disorder with milnacipran in a patient with schizophrenia.
Hung S; Hung GC
J Clin Psychopharmacol; 2014 Oct; 34(5):653-4. PubMed ID: 25076421
[No Abstract] [Full Text] [Related]
2. Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.
Yoshida K; Higuchi H; Ozaki N
Pharmacopsychiatry; 2007 Mar; 40(2):84-5. PubMed ID: 17447181
[No Abstract] [Full Text] [Related]
3. [New drug therapy of adult attention deficit hyperactivity disorder--evaluation of efficacy of milnacipran].
Masuko H
Seishin Shinkeigaku Zasshi; 2008; 110(10):908-11. PubMed ID: 19278066
[No Abstract] [Full Text] [Related]
4. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report.
Kito S; Nakajima T; Koga Y
Eur Psychiatry; 2005 Jun; 20(4):355. PubMed ID: 16018932
[No Abstract] [Full Text] [Related]
5. Remarkable effect of milnacipran in the treatment of Japanese major depressive patients.
Higuchi H; Yoshida K; Takahashi H; Naito S; Tsukamoto K; Kamata M; Ito K; Sato K; Shimizu T
Hum Psychopharmacol; 2002 Jun; 17(4):195-6. PubMed ID: 12404688
[No Abstract] [Full Text] [Related]
6. [Obsessive-compulsive symptoms in schizophrenia: remission with anti-obsessive treatment].
Payá González B; Crespo Facorro B; Sáenz Herrero M; Ayuso Gutiérrez JL
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(3):201-3. PubMed ID: 9717345
[TBL] [Abstract][Full Text] [Related]
7. Improvement of obsessions and compulsions with clozapine in an individual with schizophrenia.
Tibbo P; Gendemann K
Can J Psychiatry; 1999 Dec; 44(10):1049-50. PubMed ID: 10637686
[No Abstract] [Full Text] [Related]
8. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Leo RJ; Brooks VL
Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
[TBL] [Abstract][Full Text] [Related]
9. Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice.
Sugimoto Y; Tagawa N; Kobayashi Y; Hotta Y; Yamada J
Biol Pharm Bull; 2007 Dec; 30(12):2399-401. PubMed ID: 18057733
[TBL] [Abstract][Full Text] [Related]
10. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
Puech A; Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
[TBL] [Abstract][Full Text] [Related]
11. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247
[TBL] [Abstract][Full Text] [Related]
12. Milnacipran for the treatment of chronic pain.
Kamata M; Naito S; Takahashi H; Higuchi H
Hum Psychopharmacol; 2003 Oct; 18(7):575-6. PubMed ID: 14533142
[No Abstract] [Full Text] [Related]
13. Diagnosis and treatment of a patient with both psychotic and obsessive-compulsive symptoms.
Rodriguez CI; Corcoran C; Simpson HB
Am J Psychiatry; 2010 Jul; 167(7):754-61. PubMed ID: 20595428
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita S; Arita S
Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
[No Abstract] [Full Text] [Related]
15. Milnacipran and selective serotonin reuptake inhibitors in major depression.
Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of milnacipran: placebo-controlled trials.
Lecrubier Y; Pletan Y; Solles A; Tournoux A; Magne V
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():29-33. PubMed ID: 8923124
[TBL] [Abstract][Full Text] [Related]
17. ACS chemical neuroscience molecule spotlight on savella.
Hopkins CR
ACS Chem Neurosci; 2010 May; 1(5):345. PubMed ID: 22778830
[TBL] [Abstract][Full Text] [Related]
18. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
Obata H; Saito S; Koizuka S; Nishikawa K; Goto F
Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
[No Abstract] [Full Text] [Related]
20. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
Kanetani K; Kimura M; Endo S
J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
